InsiderTrades

Form 4 for REGN Regeneron Pharmaceuticals

Accepted 2022-03-31 00:00:00 ET · period of report 2022-03-29 · accession 0001708138-22-000030 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-03-31 2022-03-29+ REGN BROWN MICHAEL S Dir M - OptEx $374.12 +1,930 1,490 New +$722.1K
DM 2022-03-31 2022-03-29+ REGN BROWN MICHAEL S Dir S - Sale+OE $699.00 -1,930 1,082 -64% -$1.35M
DM 2022-03-31 2022-03-29+ REGN BROWN MICHAEL S Dir M - OptEx $0.00 -1,930 2,431 -44% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-03-29 M A 1,522 $374.12 2,604 D — —
2 Common Common Stock 2022-03-30 M A 408 $374.12 1,490 D — —
3 Common Common Stock 2022-03-30 S D 408 $699.00 1,082 D — —
4 Common Common Stock 2022-03-29 S D 1,522 $699.00 1,082 D — —
5 Derivative Non-Qualified Stock Option (right to buy) 2022-03-29 M D 1,522 $0.00 2,839 D $374.12 · — to 2030-01-02 1,522 Common Stock (F3) On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
6 Derivative Non-Qualified Stock Option (right to buy) 2022-03-30 M D 408 $0.00 2,431 D $374.12 · — to 2030-01-02 408 Common Stock (F3) On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.